Lexaria Bioscience Corp.
LEXX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LEXX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LEXX
Lexaria Bioscience Corp. is a biotechnology company developing its DehydraTECH drug delivery platform to improve the oral bioavailability of active pharmaceutical ingredients, with current clinical programs focused on GLP-1 drugs and hypertension.
Key risk: No revenue and ongoing losses
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of May 31, 2026.
Tracking 1 clinical trial for Lexaria Bioscience Corp..
Lexaria Bioscience Corp. is a biotechnology company developing its DehydraTECH drug delivery platform to improve the oral bioavailability of active pharmaceutical ingredients, with current clinical programs focused on GLP-1 drugs and hypertension.
- Lexaria's DehydraTECH platform is designed to enhance the oral delivery of drugs, including GLP-1 agonists and antihypertensives [sec_mda].
- The company has completed a Phase 1b IND trial (HYPER-H23-1) for hypertension and intends to commence further studies upon favorable market conditions [sec_mda · as of 2025-01-10].
- As of May 31, 2026, Lexaria reported cash and equivalents of $3.5M, zero revenue, a net loss of $2.0M, and shareholders' equity of $8.0M [sec].
- Lexaria has funded operations primarily through the sale of common stock and expects to continue incurring operating losses and negative cash flows through 2026 and beyond [sec_mda · as of 2026-07-13].
- The company has an accumulated deficit of approximately $11.9 million and $5.8 million incurred in the past two fiscal years, with expectations of continued significant operational expenses [sec_mda · as of 2025-11-28].
What works
- DehydraTECH platform has potential to improve oral bioavailability of GLP-1 drugs, which could address the large injectable-to-oral market shift [sec_mda · as of 2025-01-10].
- Lexaria has ongoing R&D programs in both GLP-1 and hypertension, targeting two large therapeutic areas [sec_mda · as of 2026-07-13].
- The company has a going concern assumption and has maintained working capital, with net working capital of $5.9M as of February 28, 2025 [sec_mda · as of 2025-04-14].
What to weigh
- Lexaria has no revenue and expects to continue incurring operating losses and negative cash flows for the foreseeable future [sec_mda · as of 2026-07-13].
- The company has funded operations primarily through equity sales, which may result in dilution to existing stockholders [sec_mda · as of 2026-07-13].
- The hypertension Phase 1b IND trial commencement is contingent on raising sufficient capital under favorable market conditions, creating uncertainty [sec_mda · as of 2025-01-10].
- Lexaria has an accumulated deficit of $11.9 million and $5.8 million in the past two fiscal years, with no near-term path to profitability [sec_mda · as of 2025-11-28].
From the filings
Quoted directly from source documents.
Lexaria expects continued operating losses and negative cash flows through 2026 and beyond.
“As we move forward with our planned R&D studies, we anticipate that we will continue to incur operating losses and negative cash flows for the foreseeable future covering 2026 and beyond.”
SEC MD&A · July 13, 2026
The company has funded operations primarily through common stock sales.
“Through May 31, 2026, we have funded our operations primarily through the proceeds from the sale of common stock.”
SEC MD&A · July 13, 2026
Lexaria has an accumulated deficit of $11.9 million and $5.8 million in the past two fiscal years.
“million, of which approximately $11.9 million and $5.8 million were incurred, respectively, in the past two fiscal years.”
SEC MD&A · November 28, 2025
The hypertension Phase 1b trial is contingent on raising capital under favorable market conditions.
“The Company intends to raise sufficient capital to commence this study in due course, upon more favorable financial market conditions.”
SEC MD&A · January 10, 2025
Risks & what to watch (4)›
Key risks
- No revenue and ongoing losses — Lexaria has zero revenue and expects continued operating losses and negative cash flows through 2026 and beyond [sec_mda · as of 2026-07-13].
- Dependence on equity financing — Operations funded primarily through common stock sales, leading to potential dilution for existing stockholders [sec_mda · as of 2026-07-13].
- Clinical trial uncertainty — Hypertension Phase 1b trial commencement depends on raising sufficient capital under favorable market conditions [sec_mda · as of 2025-01-10].
- Accumulated deficit — Accumulated deficit of $11.9M and $5.8M in the past two fiscal years, with no near-term profitability [sec_mda · as of 2025-11-28].
What to watch
- Progress of GLP-1 oral formulation studies and any new clinical data [sec_mda · as of 2026-07-13].
- Ability to raise capital for the hypertension Phase 1b IND trial (HYPER-H23-1) [sec_mda · as of 2025-01-10].
- Changes in cash position and burn rate, especially given the $3.5M cash as of May 31, 2026 [sec].
- Any licensing or collaboration agreements that could provide non-dilutive funding [sec_mda · as of 2026-07-13].
Sources: SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Lexaria Bioscience Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lexaria Bioscience Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
6.7 months
D/E 0.09
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
27
Total value held
$1.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 444,586 | $347K |
| invenomic capital management lp | 442,301 | $345K |
| geode capital management, llc | 294,157 | $229K |
| toronto dominion bank | 140,013 | $109K |
| vanguard fiduciary trust co | 94,166 | $73K |
| state street corp | 39,301 | $31K |
| blackrock, inc. | 27,445 | $21K |
| xtx topco ltd | 25,067 | $20K |
| krilogy financial llc | 19,653 | $19K |
| vontobel holding ltd. | 23,000 | $18K |
Showing top 10 of 27 institutional holders of Lexaria Bioscience Corp.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 1.5%
- Days to cover
- 1.5
- Shares short
- 346,201
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LEXX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Lexaria Bioscience Corp.?
Lexaria Bioscience Corp. is a biotechnology company developing its DehydraTECH drug delivery platform to improve the oral bioavailability of active pharmaceutical ingredients, with current clinical programs focused on GLP-1 drugs and hypertension.
Who is the CEO of Lexaria Bioscience Corp.?
Mr. Richard C. Christopher is the chief executive officer of Lexaria Bioscience Corp. (LEXX).
Where is Lexaria Bioscience Corp. headquartered?
Lexaria Bioscience Corp. (LEXX) is headquartered in Kelowna, BC, Canada.
What therapeutic areas does Lexaria Bioscience Corp. focus on?
Lexaria Bioscience Corp. develops therapies across Oncology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.